Characterization of somatostatin receptor 2 and 5 expression in operable hepatocellular carcinomas

Hepato-Gastroenterology

Volumn 59, Issue 119, 2012, Pages 2054-2058

  Li, Shanni ^a   Liu, Yao ^b   Shen, Zhong Yang ^a  

^a Tianjing First Center Hospital   (China)

^b GRADUATE SCHOOL OF PEKING UNION MEDICAL COLLEGE   (China)

Author keywords

Hepatocellular carcinoma; Overall survival; QPCR; Somatostatin receptor

Indexed keywords

MESSENGER RNA; SOMATOSTATIN RECEPTOR 2; SOMATOSTATIN RECEPTOR 5;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; CLINICAL FEATURE; CONTROLLED STUDY; FEMALE; FOLLOW UP; GENE EXPRESSION; GENETIC ASSOCIATION; HEPATITIS B; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; SURVIVAL TIME;

ADULT; AGED; CARCINOMA, HEPATOCELLULAR; CHI-SQUARE DISTRIBUTION; DISEASE-FREE SURVIVAL; DOWN-REGULATION; FEMALE; HEPATITIS B; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROPORTIONAL HAZARDS MODELS; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, SOMATOSTATIN; RISK FACTORS; RNA, MESSENGER; TIME FACTORS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84872057509     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: 10.5754/hge12357     Document Type: Article

References (21)

1. Sia D, Villanueva A: Signaling pathways in hepatocellular carcinoma. Oncology 2011; 81(1):18-23.
2. Zheng Yu, Sun Peng, Pan Hong-Ming, et al.: Expression of multi-drug resistance-related genes MDR3 and MRP as prognostic factors in clinical liver cancer patients. Hepato-gastroenterol 2012; 59(117); Epub ahead of print.
3. El-Serag HB, Siegel AB, Davila JA, et al.: Treatment and outcomes of treating of hepatocellular carcinoma among Medicare recipients in the United States: a population-based study. J Hepatol 2006; 44:158-166.
4. Yeh CN, Chen MF, Lee WC, Jeng LB: Prognostic factors of hepatic resection for hepatocellular carcinoma with cirrhosis: univariate and multivariate analysis. J Surg Oncol 2002; 81:195-202.
5. Nagasue N, Ono T, Yamanoi A, et al.: Prognostic factors and survival after hepatic resection for hepatocellular carcinoma without cirrhosis. Br J Surg 2001; 88:515-522.
6. Llovet JM: Treatment of hepatocellular carcinoma. Curr Treat Options Gastroenterol 2004; 7:431-441.
7. Zou Y, Xiao X, Li Y, et al.: Somatostatin analogues inhibit cancer cell proliferation in an SSTR2-dependent manner via both cytostatic and cytotoxic pathways. Oncol Rep 2009; 21:379-386.
8. Oberg K: Somatostatin analog octreotide LAR in gastro-enteropancreatic tumors. Expert Rev Anticancer Ther 2009; 9:557-566.
9. Strosberg J, Kvols L: Antiproliferative effect of somatostatin analogs in gastroenteropancreatic neuroendocrine tumors. World J Gastroenterol 2010; 16:2963-2970.
10. Reubi JC, Zimmermann A, Jonas S, et al.: Regulatory peptide receptors in human hepatocellular carcinomas. Gut 1999; 45:766-774.
11. Dimitroulopoulos D, Xinopoulos D, Tsamakidis K, et al.: Long acting octreotide in the treatment of advanced hepatocellular cancer and overexpression of somatostatin receptors: randomized placebo-controlled trial. World J Gastroenterol 2007; 13:3164-3170.
12. Reynaert H, Rombouts K, Vandermonde A, et al.: Expression of somatostatin receptors in normal and cirrhotic human liver and in hepatocellular carcinoma. Gut 2004; 53:1180-1189.
13. Blaker M, Schmitz M, Gocht A, et al.: Differential expression of somatostatin receptor subtypes in hepatocellular carcinomas. J Hepatol 2004; 41:112-118.
14. Kouroumalis E, Skordilis P, Thermos K, et al.: Treatment of hepatocellular carcinoma with octreotide: a randomized controlled study. Gut 1998; 42:442-447.
15. th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol 2010; 17:1471-1474.
16. Fasciani A, Quilici P, Biscaldi E, et al.: Overexpression and functional relevance of somatostatin receptor-1, -2, and -5 in endometrium and endometriotic lesions. J Clin Endocrinol Metab 2010; 95:5315-5319.
17. Raulf F, Pérez J, Hoyer D, et al.: Differential expression of five somatostatin receptor subtypes, SSTR1-5, in the CNS and peripheral tissue. Digestion 1994; 55(3):46-53.
18. Pawlikowski M, Melen-Mucha G: Perspectives of new potential therapeutic applications of somatostatin analogs. Neuro Endocrinol Lett 2003; 24:21-27.
19. Xie YM, Yan LN, Wei B, et al.: Correlation of somatostatin receptor expression in human hepatocellular carcinoma tissue to serum alpha-fetoprotein concentration. Ai Zheng 2007; 26:688-692 (Chinese with English abstract).
20. Min Li, Wei LI, Hee Joon Kim, et al.: Characterization of somatostatin receptor expression in human pancreatic cancer using real-time RT-PCR. J Surg Res 2004; 119:130-137.
21. Papotti M, Bongiovanni M, Volante M, et al.: Expression of somatostatin receptor types 1-5 in 81 cases of gastrointestinal and pancreatic endocrine tumors. A correlative immunohistochemical and reverse-transcriptase polymerase chain reaction analysis. Virchows Arch 2002; 440:461-475.